Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT01447862

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01447862
Other papers using this trial's data
  • Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2017-02-01 DOI, PubMed 28175295, PMC5400093 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01447862. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
Intervention (Drug)
Brinavess (Vernakalant)
Intervention (Drug)
Corvert (Ibutilide)
Lead sponsor
Medical University of Vienna (class: other)

Record details

Record id
cardio:ct-nct01447862
Content hash
0565c0281eacd8bb77aa60e0edc80e3e320f487c49dc9de18ccc57836e326ea1